Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCγ-activated STAT1

Bone

Volumn 41, Issue 2, 2007, Pages 273-281

  Harada, Daisuke ^a   Yamanaka, Yoshitaka ^a   Ueda, Koso ^a   Nishimura, Riko ^b   Morishima, Tsuneo ^a   Seino, Yoshiki ^c   Tanaka, Hiroyuki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c OSAKA KOSEI NENKIN HOSPITAL   (Japan)

Author keywords

ER localization; FGFR3; Phosphorylation; Skeletal dysplasia; STAT1

Indexed keywords

CASPASE; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PHOSPHOLIPASE C GAMMA; STAT1 PROTEIN;

ACHONDROPLASIA; APOPTOSIS; ARTICLE; CARTILAGE CELL; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; DWARFISM; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; KINETICS; MUTATION; PHENOTYPE; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STIMULATION; THANATOPHORIC DWARFISM;

ANIMALS; APOPTOSIS; CELL LINE; CHONDROCYTES; DWARFISM; HUMANS; MICE; MUTAGENESIS, SITE-DIRECTED; PHOSPHOLIPASE C GAMMA; PHOSPHORYLATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR;

EID: 34347259534     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.11.030     Document Type: Article

References (43)

1. Shiang R.T.L., Zhu Y.Z., Church D.M., Fielder T.J., Bocia M., Winodur S.T., et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78 (1994) 335-342
2. Rousseau F.B.J., Legeai M.L., Pelet A., Rozet J.M., Marotearx P., Le M.M., et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371 (1994) 252-254
3. Bellus G.A.M.I., Smith E.A., Aylsworth A.S., Kaitila I., Horton W.A., Greenhaw G.A., et al. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat. Genet. 10 3 (1995) 357-359
4. Bellus G.A.S.E.B., Speiser P.W., Weaver C.A., Garber A.T., Bryke C.R., Israel J., et al. Distinct missense mutations of the FGFR3 Lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am. J. Hum. Genet. 67 (2000) 1411-1421
5. Tavormina P.L., Ahiang R., Thompson L.M., Zhu Y.Z., Wilkin D.J., Lachman R.S., et al. Thanatophoric dysplasia (type I and type II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat. Genet. 9 (1995) 321-328
6. Tavormina P.L., Rimon D.L., Cohn D.H., Zhu Y.Z., Shiang R., and Wamuth J.J. Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Hum. Mol. Genet. 4 (1995) 2175-2177
7. Rousseau F., Saugier P., LeMerrer M., Munnich A., Delezoide A.L., Moroteaux P., et al. Stop codon FGFR3 mutation in thanatophoric dwarfism Type I. Nat. Genet. 10 (1995) 11-12
8. Tavormina P.L., Bellus G.A., Wbster M.K., Bamshad M.J., Fraley A.E., Mclntosh I., et al. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am. J. Hum. Genet. 64 (1999) 722-731
9. Weksler N.B., Lunstrum G.P., Reid E.S., and Horton W.A. Differential effects of fibroblast growth factor (FGF) 9 and FGF2 on proliferation, differentiation and terminal differentiation of chondrocytic cells in vitro. Biochem. J. 15 342 Pt. 3 (1999) 677-682
10. De Luca F., and Baron J. Control of bone growth by fibroblast growth factors. Trends Endocrinol. Metab. 10 2 (1999) 61-65
11. Legeai-Mallet L., Benoist-Lasselin C., Munnich A., and Bonaventure J. Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias. Bone 34 1 (2004) 26-36
12. Naski M.C., Wang Q., Xu J., and Ornitz D.M. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat. Genet. 13 (1996) 233-237
13. Lievens P.M., and Liboi E. The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. J. Biol. Chem. 278 19 (2003) 17344-17349
14. Lievens P.M.J., Mutinelli C., Daynes D., and Liboi E. The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling. J. Biol. Chem. 279 41 (2004) 43254-43260
15. Su W.C., Kitagawa M., Xue N., Xie B., Garofalo S., Cho J., et al. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 386 6622 (1997) 288-292
16. Li C., Chen L., Iwata T., Kitagawa M., Fu X.Y., and Deng C.X. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum. Mol. Genet. 8 1 (1999) 35-44
17. Hart K.C., Robertson S.C., Kanemitsu M.Y., Meyer A.N., Tynan J.A., and Donoghue D.J. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 19 29 (2000) 3309-3320
18. Sahni M., Ambrosetti D.C., Mansukhani A., Gertner R., Levy D., and Basilico C. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 13 11 (1999) 1361-1366
19. Sahni M., Raz R., Coffin J.D., Levy D., and Basilico C. STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. Development 128 11 (2001) 2119-2129
20. Chang Y.J., Holtzman M.J., and Chen C.C. Differential role of Janus family kinases (JAKs) in interferon-gamma-induced lung epithelial ICAM-1 expression: involving protein interactions between JAKs, phospholipase C gamma, c-Src, and STAT1. Mol. Pharmacol. 65 3 (2004) 589-598
21. Moran Z.W.a.M.F. Phospholipase C-γ1: a phospholipase and guanine nucleotide exchange factor. Mol. Interv. 2 6 (2002) 352-355
22. Mohammadi M., Honegger A.M., Rotin D., Fischer R., Bellot F., Li W., et al. A Tyrosine-Phosphorylated Carboxy-Terminal Peptide of the Fibroblast Growth Factor Receptor (Flg) Is a Binding Site for the SH2 Domain of Phospholipase C-gamma l. Mol Cell Biol 11 10 (1991) 5068-5078
23. Shukunami C., Shigeno C., Atsumi T., Ishizeki K., Suzuki F., and Hiraki Y. Chondrogenic differentiation of clonal mouse embryonic cell line ATDC5 in vitro: differentiation-dependent gene expression of parathyroid hormone (PTH)/PTH-related peptide receptor. J. Cell Biol. 133 2 (1996) 457-468
24. Homma Y., and Takenawa T. Inhibitory effect of src homology (SH) 2/SH3 fragments of phospholipase C-gamma on the catalytic activity of phospholipase C isoforms. Identification of a novel phospholipase C inhibitor region. J. Biol. Chem. 267 30 (1992) 21844-21849
25. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., et al. Stat3 as an oncogene. Cell 98 3 (1999) 295-303
26. Yamanaka Y., Tanaka H., Koike M., Nishimura R., and Seino Y. PTHrP rescues ATDC5 cells from apoptosis induced by FGF receptor 3 mutation. J. Bone Miner. Res. 18 (2003) 1395-1403
27. Koike M., Yamanaka Y., Inoue M., Tanaka H., Nishimura R., and Seino Y. Insulin-like growth factor-1 rescues he mutated FGF Receptor 3 (G380R) expressing ATDC5 cells from apoptosis through phosphatidylinositol 3-kinase and MAPK. J. Bone Miner. Res. 18 (2003) 2043-2051
28. Chin Y.E., Kitagawa M., Kuida K., Flavell R.A., and Fu X.Y. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol. Cell. Biol. 17 9 (1997) 5328-5337
29. Kumar A., Commane M., Flickinger T.W., Horvath C.M., and Stark G.R. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 278 5343 (1997) 1630-1632
30. Thomas M., Finnegan C.E., Rogers K.M., Purcell J.W., Trimble A., Johnston P.G., et al. STAT1: a modulator of chemotherapy-induced apoptosis. Cancer Res. 64 22 (2004) 8357-8364
31. Hart K.C., Robertson S.C., and Donoghue D.J. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, stat activation, and phosphatidylinositol 3-kinase activation. Mol. Biol. Cell 22 (2001) 931-942
32. Johnson M.R., Valentine C., Basilico C., and Mansukhani A. FGF signaling activates STAT1 and p21 and inhibits the estrogen response and proliferation of MCF-7 cells. Oncogene 16 20 (1998) 2647-2656
33. Brodie S.G., K.H., Lachman R.S., Nolasco L.M., Mekikian P.B., and Wilcox W.R. Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutations. Am. J. Med. Genet. 84 5 (1999) 476-480
34. Adar R., Monsonego-Ornan E., David P., and Yayon A. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization. J. Bone Miner. Res. 17 5 (2002) 860-868
35. Newman D.E., and Dunbar J.C. Hypochondroplasia. J. Can. Assoc. Radiol. 26 2 (1975) 95-103
36. McAlister W.H., Crane J.P., Bucy R.P., and Craig R.B. A new neonatal short limbed dwarfism. Skelet. Radiol. 13 4 (1985) 271-275
37. Elejalde B.R., and de Elejalde M.M. Thanatophoric dysplasia: fetal manifestations and prenatal diagnosis. Am. J. Med. Genet. 22 4 (1985) 669-683 [Dec.]
38. Ornitz D.M. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev. 16 (2005) 205-213
39. L'Hote C.G.M., and Knowles M.A. Cell responses to FGFR3 signaling: growth, differentiation and apoptosis. Exp. Cell Res. 304 (2005) 417-431
40. Raucci A., Laplantine E., Mansukhani A., and Basilico C. Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes. J. Biol. Chem. 279 (2004) 1747-1756
41. Hamada T., Suda N., and Kuroda T. Immunohistochemical localization of fibroblast growth factor receptors in the rat mandibular condylar cartilage and tibial cartilage. J. Bone Miner. Metab. 17 4 (1999) 274-282
42. Chen J., Williams I.R., Lee B.H., Duclos N., Huntly B.J., Donoghue D.J., et al. Constitutively activated FGFR3 mutants signal through PLC{gamma}-dependent and -independent pathways for hematopoietic transformation. Blood 106 1 (2005) 328-337 [July 1]
43. Lievens P.M., Roncador A., and Liboi E. K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2alpha and PLC gamma-independent pathways. J. Mol. Biol. 357 3 (2006) 783-792 [Mar 31]